Showing posts with label Immunization. Show all posts
Showing posts with label Immunization. Show all posts

Thursday, October 29, 2015

A Cluster Randomised Trial on the Impact of Integrating Early Infant HIV Diagnosis with the Expanded Programme on Immunization on Immunization and HIV Testing Rates in Rural Health Facilities in Southern Zambia

We assessed the integration of early infant HIV diagnosis with the expanded programme for immunization in a rural Zambian setting with the aim of determining whether infant and postpartum maternal HIV testing rates would increase without harming immunization uptake.

In an unblinded, location stratified, cluster randomised controlled trial, 60 facilities in Zambia’s Southern Province were equally allocated to a control group, Simple Intervention group that received a sensitization meeting and the resupply of HIV testing commodities in the event of a stock-out, and a Comprehensive Intervention group that received the Simple Intervention as well as on-site operational support to facilitate the integration of HIV testing services with EPI.

The average change in number of first dose diphtheria, pertussis, and tetanus vaccine (DPT1) provided per month, per facility was approximately 0.86 doses higher [90% confidence interval (CI) -1.40, 3.12] in Comprehensive Intervention facilities compared to the combined average change in the Simple Intervention and control facilities. The interventions resulted in a 16.6% [90% CI: -7%, 46%, P-value = 0.26] and 10% [90% CI: -10%, 36%, P-value = 0.43] greater change in average monthly infant DBS testing compared to control for the Simple and Comprehensive facilities respectively. We also found 15.76 (90% CI: 7.12, 24.41, P-value < 0.01) and 10.93 (90% CI: 1.52, 20.33, P-value = 0.06) additional total maternal re-tests over baseline for the Simple and Comprehensive Facilities respectively.

This study provides strong evidence to support Zambia’s policy of integration of HIV testing and EPI services. Actions in line with the interventions, including HIV testing material supply reinforcement, can increase HIV testing rates without harming immunization uptake. In response, Zambia’s Ministry of Health issued a memo to remind health facilities to provide HIV testing at under-five clinics and to include under-five HIV testing as part of district performance assessments.

Below:  The average number of infant DBS testing during baseline and intervention periods per facility, by intervention. The blue bars represent the average number of infant DBS tests per facility in each study arm at baseline. The red bars represent the corresponding average number of infant DBS tests during the six month intervention period.



Below:  The average number of monthly maternal retests during baseline and intervention per facility, by intervention arm. The bar chart displays the average number of monthly maternal retests both done at the six week under-five visit, as well as the total number of monthly maternal retests during the baseline and the intervention periods across the three intervention arms. The bars in blue represent values at baseline, while bars in red represent values during the six month intervention period.



Full article at: http://goo.gl/7Celu1

By:
Paul C. Wang, Benjamin J. Brockman, Alison L. Connor
IDinsight Zambia, IDinsight, Lusaka, Zambia

Albert Mwango, Simon Mutembo, Maximillian Bweupe, Pascalina Chanda-Kapata
Directorate of Disease Surveillance and Research, Ministry of Health, Lusaka, Zambia

Sarah Moberley
Applied Analytics Team, Clinton Health Access Initiative, Melbourne, Victoria, Australia

Penelope Kalesha-Masumbu
Child Health, Zambian Ministry of Community Development, Maternal and Child Health, Lusaka, Zambia

Godfrey Biemba, Davidson H. Hamer
Country Office, Zambian Centre for Applied Health Research and Development, Lusaka, Zambia

Godfrey Biemba, Davidson H. Hamer
Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America

Davidson H. Hamer
Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America

Benjamin Chibuye
Country Office, Clinton Health Access Initiative, Lusaka, Zambia

Elizabeth McCarthy
Applied Analytics Team, Clinton Health Access Initiative, Lusaka, Zambia
  


Thursday, July 30, 2015

A Cost-Utility Analysis of Cervical Cancer Screening and Human Papillomavirus Vaccination in the Philippines

Below: Costs and health outcomes of optimal strategies for the prevention of cervical cancer



Below:  Efficiency frontier curve of optimal cervical cancer prevention strategies at varying coverage scenarios




Below:  Model validation




Across all coverage scenarios, VIA has been shown to be a dominant and cost-saving screening strategy with incremental cost-effectiveness ratio (ICER) ranging from dominant to Php 61,059 (1443 USD) per QALY gained. VIA can reduce cervical cancer cases and deaths by 25 %. Pap smear screening was found to be not cost-effective due to its high cost in the Philippines. Adding HPV vaccination at a cost of 54 USD per vaccinated girl on top of VIA screening was found to be potentially cost-effective using a threshold of 1 GDP per capita (i.e., Php 120,000 or 2835 USD/ QALY) with the most favorable assumption of providing lifelong immunity against high-risk oncogenic HPV types 16/18. The highest incremental QALY gain was achieved with 80 % coverage of the combined strategy of VIA at 35 to 45 years old done every five years following vaccination at 11 years of age with an ICER of Php 33,126 (783 USD). This strategy may result in a two-thirds reduction in cervical cancer burden. HPV vaccination is not cost-effective when vaccine protection lasts for less than 20 years.

High VIA coverage targeting women aged 35–45 years old at five-year intervals is the most efficient and cost-saving strategy in reducing cervical cancer burden in the Philippines. Adding a vaccination program at high coverage among 11-year-old girls is potentially cost-effective in the Philippines assuming a life-long duration of vaccine efficacy.

Via:  http://ht.ly/Qj5N4  MT @BMC_series